In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Urologix Shakes Off Reimbursement Woes; Stock Is Up Nearly 80% In July

This article was originally published in The Gray Sheet

Executive Summary

Urologix' announcement that its Targis microwave system likely will be reimbursed on par with other minimally invasive therapies for benign prostatic hyperplasia under the Health Care Financing Administration's physician fee schedule signaled that the firm's payment problems may finally be coming to an end. The issue ended July up 78.5%.

You may also be interested in...

BPH Treatment Devices To Be Reimbursed By HCFA At Approximately $1,875

EDAP expects that the lower cost of its Prostatron microwave-based system for treating benign prostatic hyperplasia will make the product more attractive than competing devices now that therapy has been assigned an ambulatory payment classification (APC) code with a set reimbursement level.

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts